Grace Therapeutics (GRCE) Current Assets (2017 - 2026)
Grace Therapeutics (GRCE) posted Current Assets of $17.4 million for Q1 2026, down 9.53% sequentially from $19.2 million in Q4 2025, and down 23.48% YoY from $22.7 million in Q1 2025.
Grace Therapeutics (GRCE) Current Assets (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Current Assets for 10 years, with the latest figure at $17.4 million in Q1 2026.
- Quarterly Current Assets fell 23.48% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (down 23.48% YoY) and the FY2026 annual result came in at $17.4 million, down 23.48% from the prior year.
- Current Assets retreated to $17.4 million in Q1 2026 per GRCE's latest filing, from $19.2 million in the prior quarter.
- Over five years, Current Assets peaked at $45.3 million in Q1 2022 and troughed at $11.9 million in Q4 2024.
- A 5-year average of $25.6 million and a median of $23.6 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets slumped 55.59% in 2024, then jumped 60.91% in 2025.
- Over 5 years, Current Assets stood at $33.4 million in 2022, then slipped by 19.58% to $26.9 million in 2023, then plunged by 55.59% to $11.9 million in 2024, then soared by 60.91% to $19.2 million in 2025, then fell by 9.53% to $17.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $17.4 million, $19.2 million, and $17.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 1.76 Bn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 14.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.33 Mn |
| Mar 31, 2026 | 17.38 Mn |
| Dec 31, 2025 | 19.21 Mn |
| Sep 30, 2025 | 17.30 Mn |
| Jun 30, 2025 | 20.53 Mn |
| Mar 31, 2025 | 22.71 Mn |
| Dec 31, 2024 | 11.94 Mn |
| Sep 30, 2024 | 16.06 Mn |
| Jun 30, 2024 | 20.43 Mn |
| Mar 31, 2024 | 24.01 Mn |
| Dec 31, 2023 | 26.88 Mn |
| Sep 30, 2023 | 28.89 Mn |
| Jun 30, 2023 | 23.61 Mn |
| Mar 31, 2023 | 29.29 Mn |
| Dec 31, 2022 | 33.43 Mn |
| Sep 30, 2022 | 37.51 Mn |
| Jun 30, 2022 | 41.25 Mn |
| Mar 31, 2022 | 45.28 Mn |
| Dec 31, 2021 | 49.00 Mn |
| Sep 30, 2021 | 54.55 Mn |